腺癌
癌变
免疫组织化学
肺癌
图谱
医学
肿瘤科
内科学
下调和上调
癌症研究
生物标志物
癌症
阶段(地层学)
基因
生物
蛋白质表达
遗传学
古生物学
作者
Zhenxing Feng,Jiao Zhang,Yafang Zheng,Wang Qing-zhang,Xiaochuan Min,Tieshuan Tian
出处
期刊:Personalized Medicine
[Future Medicine]
日期:2021-03-01
卷期号:18 (2): 115-127
被引量:18
标识
DOI:10.2217/pme-2020-0112
摘要
Aim: ASF1 is involved in tumorigenesis. However, its possible role in lung adenocarcinoma (LUAD) is unclear. This study thus explored the role of ASF1A and ASF1B in LUAD. Materials & methods: Data from The Cancer Genome Atlas and Gene Expression Omnibus were employed to investigate ASF1A and ASF1B expression and its roles in LUAD prognosis. Immunohistochemistry was applied to determine the protein expression of ASF1B of 30 LUAD patients. Results: The upregulation of ASF1B in tumor tissues is associated with worse overall survival and progress-free survival and is correlated with advanced tumor stage and tumor development. However, aberrant expression of ASF1A was not found in LUAD and ASF1A was not related to patients’ overall survival and progress-free survival. Conclusion: ASF1B could be a promising prognostic and therapeutic biomarker in LUAD.
科研通智能强力驱动
Strongly Powered by AbleSci AI